摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(rac)-N-(4-bromo-5,6,7,8-tetrahydro-isoquinolin-8-yl)-propionamide | 1428651-96-0

中文名称
——
中文别名
——
英文名称
(rac)-N-(4-bromo-5,6,7,8-tetrahydro-isoquinolin-8-yl)-propionamide
英文别名
N-(4-bromo-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide;N-(4-Bromo-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide;N-(4-bromo-5,6,7,8-tetrahydroisoquinolin-8-yl)propanamide
(rac)-N-(4-bromo-5,6,7,8-tetrahydro-isoquinolin-8-yl)-propionamide化学式
CAS
1428651-96-0
化学式
C12H15BrN2O
mdl
——
分子量
283.168
InChiKey
HDHLVCVQEDWFPK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    433.6±45.0 °C(Predicted)
  • 密度:
    1.43±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (rac)-N-(4-bromo-5,6,7,8-tetrahydro-isoquinolin-8-yl)-propionamide4-氯-2-氟苯硼酸四(三苯基膦)钯 、 sodium carbonate 作用下, 以 乙醇 为溶剂, 反应 16.0h, 以70%的产率得到(rac)-N-(4-(4-chloro-2-fluorophenyl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide
    参考文献:
    名称:
    Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys
    摘要:
    Inappropriately high levels of aldosterone are associated with many serious medical conditions, including renal and cardiac failure. A focused screen hit has been optimized into a potent and selective aldosterone synthase (CYP11B2) inhibitor with in vitro activity against rat, mouse, human, and cynomolgus monkey enzymes, showing a selectivity factor of 160 against cytochrome CYP11B1 in the last species. The novel tetrahydroisoquinoline compound (+)-(R)-6 selectively reduced aldosterone plasma levels in vivo in a dose-dependent manner in db/db mice and cynomolgus monkeys. The selectivity against CYP11B1 as predicted by cellular inhibition data and free plasma fraction translated well to Synacthen challenged cynomolgus monkeys up to a dose of 0.1 mg kg(-1). This compound, displaying good in vivo potency and selectivity in mice and monkeys, is ideally suited to perform mechanistic studies in relevant rodent models and to provide the information necessary for translation to non-human primates and ultimately to man.
    DOI:
    10.1021/acs.jmedchem.5b00851
  • 作为产物:
    参考文献:
    名称:
    [EN] NEW PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES
    [FR] NOUVEAUX DÉRIVÉS DE PHÉNYL-TÉTRAHYDROISOQUINOLINE
    摘要:
    这项发明提供了具有通式(I)的新化合物,其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A和n如本文所述,包括这些化合物的组合物以及使用这些化合物的方法。
    公开号:
    WO2013156423A1
点击查看最新优质反应信息

文献信息

  • PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES
    申请人:HOFFMANN-LA ROCHE INC.
    公开号:US20130274287A1
    公开(公告)日:2013-10-17
    The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , A and n are as described herein, compositions including the compounds and methods of using the compounds.
    这项发明提供了具有通式(I)的新化合物,其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A和n如本文所述,包括这些化合物的组合物以及使用这些化合物的方法。
  • [EN] NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS BICYCLIQUES DE LA DIHYDROISOQUINOLINE-1-ONE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2013079452A1
    公开(公告)日:2013-06-06
    The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4¸ R5, R6, A1, A2, A3, A4, A5 and n are as described herein,compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrom.
    该发明提供了具有一般式(I)的新化合物,其中R1、R2、R3、R4、R5、R6、A1、A2、A3、A4、A5和n如本文所述,包括这些化合物的组合物以及将这些化合物用作醛固酮合成酶(CYP11B2或CYP11B1)抑制剂治疗或预防慢性肾病、充血性心力衰竭、高血压、原发性醛固酮增多症和库欣综合征的方法。
  • NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES
    申请人:Aebi Johannes
    公开号:US20130079365A1
    公开(公告)日:2013-03-28
    The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , A 1 , A 2 A 3 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds of the present invention are useful as inhibitors of aldosterone synthase. The compounds may be used, for example, in the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
    这项发明提供了具有一般式(I)的新化合物,其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A1、A2、A3和n如本文所述,包括这些化合物的组合物和使用这些化合物的方法。本发明的化合物可用作醛固酮合酶的抑制剂。这些化合物可以用于慢性肾病、充血性心力衰竭、高血压、原发性醛固酮分泌过多症和库欣综合征的治疗或预防。
  • [EN] NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS BICYCLIQUES DE DIHYDROQUINOLINE-2-ONE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2013041591A1
    公开(公告)日:2013-03-28
    The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4¸ R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 A3 and n are as described herein, compositions including the compounds and methods of using the compounds.
    这项发明提供了具有一般式(I)的新化合物,其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A1、A2、A3和n如本文所述,包括这些化合物的组合物以及使用这些化合物的方法。
  • NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES
    申请人:Hoffmann-La Roche Inc.
    公开号:US20130143863A1
    公开(公告)日:2013-06-06
    The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A 1 , A 2 , A 3 , A 4 , A 5 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful, for example, as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
    这项发明提供了具有一般式(I)的新化合物,其中R1、R2、R3、R4、R5、R6、A1、A2、A3、A4、A5和n如本文所述,包括这些化合物的组合物以及使用这些化合物的方法。这些化合物可用作醛固酮合酶(CYP11B2或CYP11B1)抑制剂,用于治疗或预防慢性肾脏疾病、充血性心力衰竭、高血压、原发性醛固酮增多症和库欣综合征。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-